Understanding the Mechanism and Sensitivity of BCL-2 Inhibitors
John Seymour, MBBS, FRACP, PhD, explains the mechanism of action of BCL-2 inhibitors like venetoclax.
Related Articles
Community Practice Training During Fellowship Often Falls Short
A hematology fellow discusses findings from 2 surveys he coauthored, which sought to identify gaps in community practice training during hematology/oncology fellowship.
Options for MRD Testing Affect Patient Treatment Plan in Lung Cancer
Luis E. Raez, MD, discusses when minimal residual disease testing can be performed as an option for patients with lung cancer.
Richard Pazdur, FDA Cancer Chief, Discusses 25 Years of Innovation
Dr. Richard Pazdur for 25 years has overseen innovations in the treatment of deadly diseases at the agency.
Transplant and Nontransplant Salvage Therapy in Pediatric Relapsed or Refractory Hodgkin Lymphoma
This nonrandomized clinical trial in pediatric relapsed classic Hodgkin lymphoma tested fludeoxyglucose-18 positron emission tomography scans to identify patients in whom transplant-free salvage therapy would…
Subcutaneous Isatuximab Combo Hits Primary End Points in Phase 3 Trial
The phase 3 IRAKLIA trial of subcutaneous isatuximab met its co-primary end points in multiple myeloma.
3 QUESTIONS ON . . . ‘Spillover’ Savings for the Oncology… : Oncology Times
An abstract is unavailable.
Program: Tuesday, February 25
tuesday, february 25 *-Short talk from proffered abstract CONTINENTAL BREAKFAST 7-8 a.m. Major Symposia 4-5 8-9:30 a.m. Major Symposium 4: Neoadjuvant Immunotherapy Session Chair: Christian…
Nivolumab Plus Ipilimumab Wins European Approval for MSI-H/dMMR mCRC
Nivolumab plus ipilimumab has been approved in Europe for the frontline treatment of adult patients with MSI-H or dMMR metastatic colorectal cancer.
‘All for one’: City of Hope oncologist focuses on patients after evacuating fires
Ravi Salgia, MD, PhD, and his family were watching coverage of the Los Angeles County fires on their television around 6 p.m. Jan. 7 when…
